Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07625215 · ClinicalTrials.gov registry record · Phase 2
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
A Phase 2 study, sponsored by Bayer.
- Not yet
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT07625215 is a Phase 2 study that has not yet begun recruiting, run by Bayer. The registered enrollment target is 360 participants.
The verdict
NCT07625215, a Phase 2 study, has not yet begun recruiting, sponsored by Bayer.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion. Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body. The total duration of the study for an individual participant may be up two months. The findings from this study may contribute to the development of a new treatment option for people with AF.
Interventions
- OTHER Placebo
- DRUG BAY 3670549
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2026-07-17 |
| Est. Completion | 2030-05-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07625215
The ClinicalTrials.gov registry entry for NCT07625215 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07625215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07625215 about?
NCT07625215 is a clinical study titled "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation". The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called ele...
What is the current status of trial NCT07625215?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2026-07-17. Estimated completion is 2030-05-16.
What interventions are being tested in trial NCT07625215?
The interventions under investigation include: Placebo (OTHER), BAY 3670549 (DRUG).
Who is sponsoring clinical trial NCT07625215?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.